"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemp Clin Trials. 2024 Nov; 146:107690.
-
Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 Sep 03; 7(9):e2434704.
-
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers. J Psychopharmacol. 2024 Nov; 38(11):986-997.
-
Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021. JAMA. 2024 02 13; 331(6):524-526.
-
Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend. 2023 09 01; 250:110911.
-
Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series. Addict Sci Clin Pract. 2023 06 01; 18(1):38.
-
Treatment of opioid use disorder in Ukraine during the first year of the Russia-Ukraine war: Lessons learned from the crisis. Int J Drug Policy. 2023 Jul; 117:104062.
-
Predictive Factors Associated with Naloxone Prescription among Pregnant People Admitted for the Management of Opioid Use Disorder. Am J Perinatol. 2024 04; 41(5):539-542.
-
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings. PLoS One. 2022; 17(10):e0276066.
-
Overcoming challenges in acute care hospitalizations for patients with opioid use disorder. J Am Pharm Assoc (2003). 2023 Jan-Feb; 63(1):204-211.e2.